Avantor (NYSE:AVTR) Posts Earnings Results, Beats Estimates By $0.01 EPS

Avantor (NYSE:AVTR) announced its quarterly earnings results on Wednesday. The company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.21 by $0.01, FiscalAI reports. The company had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter in the prior year, the company earned $0.22 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis.

Here are the key takeaways from Avantor’s conference call:

• Avantor returned to organic revenue growth in Q3, with revenue up 5.2% organically to $1.698 billion. VWR grew 5.8%, while Bioscience & Medtech Products returned to growth at 3.6%, supported by improved execution and stronger demand.
• Management raised its 2026 outlook, now expecting organic revenue growth of 0.75%–1.25%, adjusted EPS of $0.81–$0.83, and free cash flow of $525–$550 million. The company expects adjusted net leverage to fall below 3.0x by year-end, compared with 3.1x at the end of Q3.
• The company cited continued momentum from its Revival program, including improved manufacturing throughput, supply-chain execution, customer service, e-commerce, and AI-enabled commercial tools. BMP also reported positive book-to-bill trends and strong performance in Process Chemicals and NuSil.
• Profitability remains pressured by product and customer mix, inflation, and targeted growth investments, particularly in VWR. Management said 2026 pricing of roughly 1%–2% has not fully offset inflation, while Europe remains a weak market and BMP faces approximately 400 basis points of discrete comparison headwinds in Q4.

Avantor Stock Performance

AVTR traded down $0.74 during trading hours on Wednesday, hitting $16.39. 10,506,330 shares of the stock were exchanged, compared to its average volume of 10,117,616. The stock has a 50-day simple moving average of $15.34 and a 200-day simple moving average of $11.18. Avantor has a 12 month low of $7.26 and a 12 month high of $17.45.

Key Headlines Impacting Avantor

Here are the key news stories impacting Avantor this week:

• Positive Sentiment: Avantor reported net sales of $1.698 billion, up 4.6% year over year and ahead of the $1.64 billion consensus estimate. Organic sales increased 5.2%, indicating improving underlying demand across the business. Avantor Reports Third Quarter 2026 Results
• Positive Sentiment: Adjusted earnings were $0.22 per share, exceeding the $0.21 analyst consensus and matching the prior-year result. Diluted GAAP EPS was $0.30. The revenue and earnings beats support the recent increase in AVTR’s share price and suggest execution is improving. Avantor Surpasses Q3 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its full-year 2026 organic revenue growth, adjusted EPS and free-cash-flow guidance after results exceeded expectations. Higher guidance is likely the most important bullish development for investors because it improves the outlook for future earnings and cash generation. Avantor Guidance Update
• Neutral Sentiment: Avantor appointed Mikey Santiago as chief information officer to lead its global IT strategy. The change may support operational efficiency over time but is unlikely to materially affect near-term trading. Avantor Appoints New Chief Information Officer
• Negative Sentiment: Barclays maintained a Sell rating and a $15 price target, below AVTR’s recent trading level. This signals that some analysts remain concerned about valuation or the durability of the recovery despite the upbeat quarter. Barclays Maintains Sell Rating on Avantor

Analysts Set New Price Targets

Several analysts have recently weighed in on AVTR shares. Barclays boosted their target price on Avantor from $13.00 to $15.00 and gave the company an “underweight” rating in a report on Wednesday, October 7th. TD Cowen increased their price target on shares of Avantor from $15.00 to $17.00 and gave the company a “hold” rating in a report on Tuesday, October 13th. Royal Bank Of Canada raised their price objective on shares of Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 30th. Citigroup raised their price objective on Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Finally, Wall Street Zen raised Avantor from a “hold” rating to a “buy” rating in a research note on Sunday, October 11th. One investment analyst has rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $13.06.

About Avantor

Avantor, Inc is a global provider of mission-critical products and services used in the life sciences, healthcare, education, and advanced technology industries. The company supplies chemicals, reagents, laboratory consumables, equipment, and other materials used in research, development, manufacturing, and quality-control activities.

Avantor also provides specialized solutions for biopharmaceutical production, including materials and services that support drug development, biologics manufacturing, and other bioprocessing applications.